Abstract
Protein kinases are enzymes assuring the transfer of a phosphate group of molecule donors of high energy, such as ATP, in specific substrates. The disorder of these enzymes in cellular environment are involved in some pathologies such as cancer and Alzheimer's disease [1]. So the discovery of inhibitors became the key point for the research of new therapeutic agents. In our team, N,N'-bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)aminopropylpiperazine (IC50=40 nM) was identified as promising and selective inhibitor [2, 3] of DYRK1A (dual specificity, tyrosine phosphorylation regulated kinases), a protein kinase of interest for neurodegenerative diseases [4, 5] and also for cancer [6]. In order to understand the mechanism of action of this inhibitor towards DYRK1A but also towards GSK3a/b (who also plays an important role in malaria), we have developed a 4-steps synthesis from the commercial reagents N,N'-bis(3-aminopropyl)piperazine. The key step of this process is the construction of the 2-thioxo-1,3-thiazolidine-4-one platform under microwave irradiation from commercial bis(carboxymethyl)trithiocarbonate. Results for the synthesis will be presented and discussed in this presentation .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.